《新股表现》康龙化成(03759.HK)收42.25元高上市价7% 每手账面赚275元
康龙化成(北京)新药技术股份(03759.HK)首日挂牌,股价高开10%报43.45元,最高见43.85元遇压,午後曾回顺至41.6元,全日收42.25元,较上市价39.5元,高2.75元或约7%,成交5,197万股,涉资22.26亿元。不计手续费,每手100股,账面赚275元。
康龙化成是一家领先的全流程一体化医药研发服务平台,业务遍及全球,致力於协助客户加速药物创新。银据弗若斯特沙利文资料,按2018年总收益计,康龙化是中国第二大医药研发服务平台及全球三大药物发现服务供应商之一。
是次来港上市共发售1.165亿股H股,而八名基石机构投资者合共认购3,172.63万股H股;其中10%公开发售获逾113倍超购,启动回拨机制後占比增至50%,申请一手中?率100%,股份以招股范围(34.5-39.5元)上限定价,料集资净额43.44亿元,主要用作扩展中国实验室与生产设施的产能、建立研发生物制剂的医药研发服务平台、扩展临床开发服务、潜在收购合同研发服务商及用於扩张美国及英国业务等。上市联席保荐人分别为高盛、中信里昂证券及东方证券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.